Gregory J Riggins

List of Publications by Year
in descending order

44 papers	14,058 citations	279798 23 h-index	276875 41 g-index
45 all docs	45 docs citations	45 times ranked	17591 citing authors

#	Article	IF	Citations
1	IDH1andIDH2Mutations in Gliomas. New England Journal of Medicine, 2009, 360, 765-773.	27.0	5,285
2	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science, 2008, 321, 1807-1812.	12.6	5,230
3	Mutations of mitotic checkpoint genes in human cancers. Nature, 1998, 392, 300-303.	27.8	1,400
4	Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses. Science Translational Medicine, 2014, 6, 249ra111.	12.4	285
5	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	1.8	213
6	Disruption of aÂself-amplifying catecholamine loop reduces cytokine release syndrome. Nature, 2018, 564, 273-277.	27.8	193
7	Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology, 2011, 13, 974-982.	1.2	154
8	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4, 1737-1747.	1.8	141
9	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nature Communications, 2019, 10, 943.	12.8	132
10	Molecular targeting of glioblastoma: Drug discovery and therapies. Trends in Molecular Medicine, 2011, 17, 301-312.	6.7	114
11	Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology, 2015, 17, 545-554.	1.2	78
12	Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor. Molecular Cancer Therapeutics, 2015, 14, 3-13.	4.1	78
13	Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Clinical Cancer Research, 2015, 21, 3462-3470.	7.0	66
14	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications, 2018, 9, 1057.	12.8	66
15	Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget, 2015, 6, 5536-5546.	1.8	65
16	Yes-Associated Protein 1 Is Activated and Functions as an Oncogene in Meningiomas. Molecular Cancer Research, 2012, 10, 904-913.	3.4	57
17	Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget, 2016, 7, 68571-68584.	1.8	56
18	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-Oncology, 2019, 21, 189-200.	1.2	49

#	Article	IF	Citations
19	Caveolin-1, caveolae, and glioblastoma. Neuro-Oncology, 2012, 14, 679-688.	1.2	48
20	The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. Toxicology in Vitro, 2015, 29, 2038-2044.	2.4	44
21	Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. Journal of Neuro-Oncology, 2018, 140, 529-538.	2.9	34
22	Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma. ACS Chemical Biology, 2018, 13, 3206-3216.	3.4	27
23	Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro-Oncology, 2010, 12, 655-663.	1.2	26
24	Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines. PLoS ONE, 2016, 11, e0150271.	2.5	21
25	Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene Therapy, 2019, 26, 277-286.	4.5	21
26	The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. Neuro-Oncology Advances, 2021, 3, vdaa149.	0.7	21
27	Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer. Oncotarget, 2021, 12, 1326-1338.	1.8	18
28	Somatic retrotransposition is infrequent in glioblastomas. Mobile DNA, 2016, 7, 22.	3.6	17
29	Matrix protease production, epithelial-to-mesenchymal transition marker expression and invasion of glioblastoma cells in response to osmotic or hydrostatic pressure. Scientific Reports, 2020, 10, 2634.	3.3	15
30	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. Journal of Neuro-Oncology, 2015, 121, 479-487.	2.9	14
31	Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy. SLAS Technology, 2019, 24, 28-40.	1.9	14
32	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. Neuro-Oncology Advances, 2021, 3, vdaa154.	0.7	13
33	Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks. Oncotarget, 2017, 8, 25955-25962.	1.8	11
34	EFFECT OF THE ANTIPARASITIC DRUG MEBENDAZOLE ON CHOLANGIOCARCINOMA GROWTH. Southeast Asian Journal of Tropical Medicine and Public Health, 2014, 45, 1264-70.	1.0	10
35	Molecular Study of Thyroid Cancer in World Trade Center Responders. International Journal of Environmental Research and Public Health, 2019, 16, 1600.	2.6	9
36	A role for caveolaâ€forming proteins caveolinâ€1 and CAVIN1 in the proâ€invasive response of glioblastoma to osmotic and hydrostatic pressure. Journal of Cellular and Molecular Medicine, 2020, 24, 3724-3738.	3.6	9

#	Article	IF	Citations
37	Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1. Journal of Neuro-Oncology, 2019, 143, 207-220.	2.9	8
38	Postâ€9/11 excess risk of thyroid cancer: Surveillance or exposure?. American Journal of Industrial Medicine, 2021, 64, 881-884.	2.1	6
39	Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. Neuro-Oncology, 2022, 24, 711-723.	1.2	5
40	Neutrophil depletion enhanced the Clostridium novyi-NT therapy in mouse and rabbit tumor models. Neuro-Oncology Advances, 2022, 4, vdab184.	0.7	3
41	Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1. Genes, 2020, 11, 762.	2.4	2
42	ET-08 * DEMETHYLATING THERAPY INDUCES DIFFERENTATION AND THERAPEUTIC RESPONSE IN IDH1 MUTANT MALIGNANT GLIOMAS. Neuro-Oncology, 2014, 16, v80-v80.	1.2	0
43	CADD-27. G-QUADRUPLEX DNA DRIVES GENOMIC INSTABILITY AND REPRESENTS A TARGETABLE MOLECULAR ABNORMALITY IN ATRX-DEFICIENT MALIGNANT GLIOMA. Neuro-Oncology, 2018, 20, vi280-vi280.	1.2	0
44	EXTH-34. G-QUADRUPLEX DNA DRIVES GENOMIC INSTABILITY AND REPRESENTS A TARGETABLE MOLECULAR ABNORMALITY IN ATRX-DEFICIENT MALIGNANT GLIOMA. Neuro-Oncology, 2018, 20, vi92-vi92.	1.2	0